摘要
目的探讨B淋巴细胞瘤-2(B-cell lymphoma-2,Bcl-2)结合抗凋亡基因1(Bcl-2-associated athanogene 1,BAG-1)在人脑胶质瘤中的表达及临床意义。方法应用免疫组织化SP二步法,检测2009年9月至2021年9月年安徽医科大学第二附属医院的212例人脑胶质瘤标本以及10例正常脑组织标本中的BAG-1的表达,分析其与临床病理及预后的关系。结果检测到BAG-1总体的阳性表达率为61.3%,BAG-1在低级别胶质瘤(Ⅰ~Ⅱ级)和高级别胶质瘤(Ⅲ~Ⅳ级)阳性表达率分别为48.4%和71.1%(P=0.001)。BAG-1表达阴性和阳性的病人的中位生存时间分别为60个月和17个月(P<0.001)。BAG-1表达阴性和阳性的高级别胶质瘤病人中位生存时间分别为31个月和11个月(P<0.001)。BAG-1阴性和阳性表达的病人无进展中位生存时间分别为26个月和8个月(P=0.001)。结论BAG-1在人脑胶质瘤中高表达,与肿瘤的病理分级呈正相关,与病人生存时间呈负相关,BAG-1可能成为预测胶质瘤预后及化疗疗效的重要分子标志物。
Objective To investigate the expression and clinical significance of B-cell lymphoma-2-associated apoptosis gene 1(BAG-1)in human glioma.Methods Immunohistochemical SP two-step method was used to detect BAG-1 expression in 212 human glioma tissues and 10 normal brain tissues obtained from Department of Neurosurgery,The Second Affiliated Hospital of Anhui Medical University from September 2009 to September 2021,and the relationship between BAG-1 expression and clinicopathology and prognosis was analyzed.Results The overall positive expression rate of BAG-1 was 61.3%,and the positive expression rates of BAG-1 in low-grade(Ⅰ-Ⅱ)and high-grade(Ⅲ-Ⅳ)gliomas were 48.4%and 71.1%,respectively(P=0.001).The median survival time of patients with negative and positive BAG-1 expression were 60 months and 17 months,respectively(P<0.001).The median survival time of negative and positive BAG-1 expression in patients with high-grade gliomas were 31 months and 11 months,respectively(P<0.001).The median progression-free survival time of patients with negative and positive BAG-1 expressions were 26 months and 8 months,respectively(P=0.001).Conclusions BAG-1 is highly expressed in human glioma,which is positively correlated with the pathological grading of the tumor and negatively correlated with the survival time.BAG-1 may be an important molecular marker to predict the prognosis of glioma and the efficacy of chemotherapy.
作者
郭致飞
汪超
马春春
赵兵
GUO Zhifei;WANG Chao;MA Chunchun;ZHAO Bing(Department of Neurosurgery,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China;Department of Neurosurgery,Anhui Children's Hospital,Hefei,Anhui 230022,China)
出处
《安徽医药》
CAS
2022年第10期1949-1953,I0001,共6页
Anhui Medical and Pharmaceutical Journal
基金
安徽医科大学基础和临床合作研究提升计划项目(2020xkjT044)。
